Does Aetna (CVS Health) Cover Metformin?

How Aetna Classifies Metformin on Its Formulary

Generic metformin hydrochloride sits on Tier 1 of Aetna's commercial drug formulary for the FDA-approved indication of type 2 diabetes mellitus in adults, which means the member copay is typically $0 to $10 per 30-day supply. Aetna's formulary is administered through CVS Caremark, the pharmacy benefit manager (PBM) Aetna merged with as part of CVS Health. Because CVS Caremark negotiates aggressively on high-volume generics, metformin is one of the lowest-cost entries in the entire formulary.

The FDA granted original approval to metformin immediate-release (Glucophage) in 1994 for type 2 diabetes as an adjunct to diet and exercise [1]. Every generic version carries that same approved labeling. Aetna's medical and pharmacy policy documents are aligned with the American Diabetes Association (ADA) Standards of Medical Care in Diabetes, which state: "Metformin, if not contraindicated and if tolerated, is the preferred initial pharmacological agent for type 2 diabetes" [2].

Extended-release formulations (metformin ER, Glucophage XR, Fortamet, Glumetza) may land on Tier 2 or Tier 3 depending on the specific Aetna plan design, and branded versions like Glumetza carry a substantially higher cost-share. Checking the CVS Caremark formulary search tool with your specific Aetna plan ID confirms your tier assignment before the prescription is filled. A 90-day mail-order supply through CVS Caremark usually carries a lower cost-share than a 30-day retail fill, often $0 to $15 for Tier 1 generics. The UKPDS 34 trial (N=753) demonstrated that intensive metformin therapy in overweight patients with type 2 diabetes reduced any diabetes-related endpoint by 32% compared with conventional treatment (P<0.002), providing the long-term outcome data that cemented metformin's formulary priority [3].

Prior Authorization for Metformin Under Aetna Plans

For the standard type 2 diabetes indication in adults, Aetna does not require prior authorization (PA) for generic metformin immediate-release. The prescription moves straight to dispensing once the prescriber submits it electronically or on paper. Prior authorization difficulty is rated moderate-to-high only when the clinical indication falls outside the FDA label, such as polycystic ovary syndrome (PCOS), prediabetes, or weight management [4].

Aetna's PA criteria for off-label indications typically require the prescriber to document: (1) a confirmed diagnosis code (ICD-10 E11.x for type 2 diabetes, R73.09 for prediabetes, or E28.2 for PCOS), (2) a contraindication or intolerance to diet-and-exercise intervention alone, and (3) relevant laboratory values such as hemoglobin A1c, fasting glucose, or a 2-hour oral glucose tolerance test result. Without that documentation, the pharmacy claim may reject at the point of sale with a message asking for PA. The prescriber's office then submits a PA request through CoverMyMeds or directly through CVS Caremark's provider portal.

Approval timelines run 24 to 72 hours for standard reviews and up to 72 hours for urgent reviews under most state regulations [5]. The Centers for Medicare and Medicaid Services (CMS) has proposed tightening PA turnaround rules for Medicare Advantage plans to 72 hours for urgent requests [6]. Many Aetna commercial plans already meet or exceed that standard. Once approved, PA authorizations for metformin are commonly granted for 12 months before requiring renewal.

The Diabetes Prevention Program (DPP) Outcomes Study showed metformin 850 mg twice daily reduced progression from prediabetes to type 2 diabetes by 31% over 10 years (P<0.001) compared with placebo [7]. Citing that specific outcome in a PA letter strengthens the clinical argument for coverage in the prediabetes context considerably. The ADA 2024 guidelines note that metformin "may be considered" in adults with prediabetes, particularly those under age 60, with a body mass index of 35 kg/m² or higher, or with a history of gestational diabetes [2].

Step Therapy Requirements on Aetna Plans

Step therapy for metformin itself is unusual because metformin is already the first-line agent per ADA, AACE, and most payer policies. The scenario where step therapy becomes relevant is the reverse: Aetna may require documented metformin failure, intolerance, or contraindication before it will cover a more expensive second-line agent such as a GLP-1 receptor agonist (semaglutide, liraglutide), SGLT-2 inhibitor (empagliflozin, dapagliflozin), or DPP-4 inhibitor (sitagliptin) [8].

If a prescriber wants to start a patient directly on a branded agent without a metformin trial, Aetna will typically deny coverage and require either a metformin trial of at least 90 days or documented clinical contraindications. Contraindications that bypass step therapy include eGFR <30 mL/min/1.73 m², active or high-risk lactic acidosis, and severe hepatic impairment [9]. A well-documented allergy or GI intolerance causing treatment discontinuation also qualifies.

The FDA label for metformin warns against use when eGFR is <30, and advises reassessment when eGFR falls between 30 and 45 mL/min/1.73 m² [1]. Including the patient's most recent eGFR in any PA or step-therapy exception request removes ambiguity for the Aetna pharmacy reviewer. A 2022 analysis published in JAMA Internal Medicine found that step-therapy requirements in commercial plans delayed optimal diabetes pharmacotherapy by a median of 3.4 months [10]. Proactive documentation at the time of prescribing cuts that delay substantially.

The HealthRX Metformin-to-Next-Agent Coverage Framework

When a prescriber anticipates needing a second-line diabetes agent covered by Aetna, the following documentation sequence reduces denial rates based on standard Aetna step-therapy criteria:

1. Record a minimum 90-day metformin trial with the dose titrated to at least 1 to 000 mg twice daily (or maximum tolerated dose).
2. Document A1c at trial start and at 90 days.
3. Record any GI adverse effects using patient-reported outcome language ("nausea requiring dose reduction below therapeutic threshold").
4. If metformin is contraindicated, include the dated lab (eGFR, liver function tests) triggering the contraindication.
5. Submit the PA request with ICD-10 code, dated lab values, trial duration, and the specific second-line agent requested with its formulary tier.

This sequence matches the documentation checklist Aetna's clinical pharmacy team uses during PA review.

Metformin for Weight Loss: Does Aetna Cover It?

Metformin is not FDA-approved for weight loss. Its prescribing for weight management is considered off-label. Aetna's commercial pharmacy benefit does not routinely cover metformin when the sole diagnosis code submitted is obesity (ICD-10 E66.x) [11]. Coverage is more likely when weight management is documented as a secondary goal alongside a covered primary indication such as type 2 diabetes or PCOS.

Weight loss with metformin is real but modest. The DPP trial showed 2.5 kg mean weight loss at one year with metformin 850 mg twice daily versus 0.1 kg with placebo [7]. That contrasts with GLP-1 receptor agonist data: the STEP-1 trial (N=1,961) showed semaglutide 2.4 mg produced 14.9% mean body weight reduction at 68 weeks versus 2.4% with placebo (P<0.001) [12]. When weight loss is the primary clinical goal and the patient has obesity without diabetes, an FDA-approved anti-obesity medication supported by Aetna's obesity management benefit (a separate medical benefit in many plans) may be a more defensible coverage pathway than off-label metformin. Clinicians should confirm whether the patient's Aetna plan includes an obesity management or preventive care benefit under the Affordable Care Act preventive services mandate [13].

The ADA's 2024 position is clear on this point: metformin is not recommended as a primary pharmacotherapy for obesity in individuals without diabetes or prediabetes, and payer coverage policies reflect that clinical guideline [2].

How to Appeal an Aetna Denial of Metformin

Aetna denials for metformin are uncommon for the standard diabetes indication but do occur for off-label or prediabetes requests. Every denial letter Aetna issues must, under federal law, include the specific reason for denial, the criteria used, and instructions for filing an appeal [14]. The appeal pathway has two main levels.

First-level internal appeal. The prescriber or member submits a written appeal to Aetna within 180 days of the denial notice (the deadline is printed on the denial letter). The appeal must include the denial letter, a cover letter from the prescriber explaining the clinical rationale, supporting laboratory results, relevant peer-reviewed literature, and documentation of any prior treatment attempts. Aetna must respond to a standard internal appeal within 30 days, or within 72 hours for urgent appeals under the Employee Retirement Income Security Act (ERISA) and ACA requirements [14].

Second-level external review. If the internal appeal is denied, the member has the right to request an independent external review by an Independent Review Organization (IRO) accredited by URAC or NCQA. External reviewers are board-certified physicians in the relevant specialty. The IRO's decision is binding on Aetna in all states that have adopted external review statutes, which as of 2024 includes 46 states and the District of Columbia [15]. External review decisions overturn insurer denials at rates between 35% and 50% depending on the clinical category, according to data from the Kaiser Family Foundation [15].

A denial appeal letter should cite the DPP Outcomes Study's 31% reduction in diabetes progression [7] and the ADA's explicit recommendation for metformin in prediabetes management [2] when the denial involves a prediabetes indication. For a type 2 diabetes denial, citing the UKPDS 34 cardiovascular and microvascular outcome data [3] alongside the FDA-approved label [1] is usually sufficient to overturn the decision.

Manufacturer Savings Cards and Alternative Payment Options

Generic metformin manufactured by companies such as Amneal, Teva, and Mylan carries a cash price of roughly $8 to $12 per month at major pharmacy chains without any insurance or coupon applied. GoodRx, RxSaver, and similar coupon aggregators frequently bring the 500 mg or 1 to 000 mg tablet price below $10 for a 90-day supply at CVS, Walgreens, and Walmart pharmacies [16]. That cash price is often lower than the Tier 1 copay on some high-deductible Aetna plans during the deductible phase.

Manufacturer savings cards are available for branded metformin formulations such as Glumetza and Fortamet. These savings cards generally cannot be used by patients enrolled in a federal health care program, including Medicare, Medicaid, or TRICARE, under federal anti-kickback regulations [17]. Commercially insured Aetna members can legally use a savings card, but CVS Caremark's accumulator adjustment program may not count savings-card payments toward the member's out-of-pocket maximum or deductible, depending on the plan design [18]. Patients should ask the CVS Caremark member services line (the number on the back of the Aetna insurance card) whether their plan uses an accumulator adjustment program before relying on a manufacturer card.

For patients who remain uninsured or underinsured, the FDA's generic drug database confirms that over a dozen manufacturers produce metformin hydrochloride tablets, keeping market competition strong and prices low [1]. The ADA's insulin and medication affordability resources also list federally qualified health centers (FQHCs) as a source of reduced-cost prescriptions under Section 340B drug pricing [19].

Aetna Medicare Advantage Plans and Metformin Coverage

Aetna administers numerous Medicare Advantage (MA) Prescription Drug plans under the CVS Health umbrella, including Aetna Medicare Eagle, Aetna Medicare Premier, and SilverScript (a stand-alone Part D plan). Metformin is a widely available generic and appears on nearly all Part D formularies at Tier 1 or Tier 2 [20]. The Medicare Part D Low Income Subsidy (Extra Help) further reduces cost-share for qualifying beneficiaries to $0 to $4.50 per fill in 2025 [20].

Medicare does not cover metformin when billed under the pharmacy benefit for weight loss alone. However, the Medicare Diabetes Prevention Program (MDPP) expanded model covers structured lifestyle intervention for Medicare beneficiaries with prediabetes, and the ADA notes that metformin may be considered for high-risk prediabetes individuals even within the Medicare context [2]. Coverage for that specific use under Part D requires the plan's formulary to include it and the diagnosis to be documented appropriately on the claim. A 2019 systematic review in The Lancet Diabetes and Endocrinology (19 trials, N=17,769) found metformin reduced incident type 2 diabetes by 26% in people with prediabetes or impaired glucose tolerance [21]. That evidence base supports the clinical and coverage argument for prediabetes use across payer types.

Documenting Medical Necessity to Prevent Aetna Denials

The most effective way to avoid a denial is to submit complete documentation at the time of prescribing. For type 2 diabetes, the claim should carry ICD-10 E11.65 (type 2 diabetes with hyperglycemia) or the most precise applicable code. For prediabetes, R73.09 is the correct code. For PCOS with insulin resistance, E28.2 paired with E11.65 or R73.09 is appropriate. Submitting the wrong or vague code is the most common reason a straightforward metformin claim triggers a PA request unnecessarily.

The Endocrine Society's clinical practice guideline on type 2 diabetes pharmacotherapy states that metformin should be initiated at the time of diagnosis unless contraindicated, and titrated to 2 to 000 mg per day in divided doses over four to eight weeks as tolerated [22]. Documenting that titration plan in the chart note demonstrates medical necessity alignment with published guidelines and reduces the chance that a plan's utilization management team flags the claim.

Renal function monitoring matters for both clinical safety and coverage continuity. Aetna's clinical pharmacy reviewers may request updated renal labs for patients older than 65 or those with a history of chronic kidney disease when renewing a PA. The FDA label recommends checking eGFR before initiating metformin and at least annually thereafter [1]. Keeping that laboratory data current in the chart prevents coverage gaps at renewal.